Selected article for: "case control and medical study"
Author: Ji, Wonjun; Huh, Kyungmin; Kang, Minsun; Hong, Jinwook; Bae, Gi Hwan; Lee, Rugyeom; Na, Yewon; Choi, Hyoseon; Gong, Seon Yeong; Choi, Yoon-Hyeong; Ko, Kwang-Pil; Im, Jeong-Soo; Jung, Jaehun
Title: Effect of Underlying Comorbidities on the Infection and Severity of COVID-19 in Korea: a Nationwide Case-Control Study
  • Cord-id: n64t89pn
  • Document date: 2020_6_25
    • ID: n64t89pn
    Snippet: BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic is an emerging threat worldwide. It remains unclear how comorbidities affect the risk of infection and severity of COVID-19. METHODS: This is a nationwide retrospective case-control study of 219,961 individuals, aged 18 years or older, whose medical costs for COVID-19 testing were claimed until May 15, 2020. COVID-19 diagnosis and infection severity were identified from reimbursement data using diagnosis codes and on the basis of respi
    Document: BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic is an emerging threat worldwide. It remains unclear how comorbidities affect the risk of infection and severity of COVID-19. METHODS: This is a nationwide retrospective case-control study of 219,961 individuals, aged 18 years or older, whose medical costs for COVID-19 testing were claimed until May 15, 2020. COVID-19 diagnosis and infection severity were identified from reimbursement data using diagnosis codes and on the basis of respiratory support use, respectively. Odds ratios (ORs) were estimated using multiple logistic regression, after adjusting for age, sex, region, healthcare utilization, and insurance status. RESULTS: The COVID-19 group (7,341 of 219,961) was young and had a high proportion of female. Overall, 13.0% (954 of 7,341) of the cases were severe. The severe COVID-19 group had older patients and a proportion of male ratio than did the non-severe group. Diabetes (odds ratio range [ORR], 1.206–1.254), osteoporosis (ORR, 1.128–1.157), rheumatoid arthritis (ORR, 1.207–1.244), substance use (ORR, 1.321–1.381), and schizophrenia (ORR, 1.614–1.721) showed significant association with COVID-19. In terms of severity, diabetes (OR, 1.247; 95% confidential interval, 1.009–1.543), hypertension (ORR, 1.245–1.317), chronic lower respiratory disease (ORR, 1.216–1.233), chronic renal failure, and end-stage renal disease (ORR, 2.052–2.178) were associated with severe COVID-19. CONCLUSION: We identified several comorbidities associated with COVID-19. Health care workers should be more careful while diagnosing and treating COVID-19 when patients have the abovementioned comorbidities.

    Search related documents:
    Co phrase search for related documents
    • ace receptor and liver cirrhosis: 1
    • ace receptor and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acquire infection and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acquire infection and low prevalence: 1, 2
    • acquire infection and low respiratory: 1
    • acquire infection and lung disease: 1, 2, 3, 4
    • actual population and acute respiratory syndrome: 1, 2, 3, 4, 5
    • actual population and lung disease: 1
    • acute respiratory syndrome and liver cirrhosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and local drive: 1, 2, 3
    • acute respiratory syndrome and low prevalence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and low respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and low respiratory disease: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome and low socioeconomic status: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • liver cirrhosis and low prevalence: 1, 2, 3
    • liver cirrhosis and low respiratory: 1
    • liver cirrhosis and lung disease: 1, 2, 3, 4
    • local drive and low prevalence: 1